MBI News - News & Events - MacDougall Biomedical Communications

	Home \| Sitemap \| Contact Us \| Share \| About Us Services Clients Creative Services News & Events
	News & Events Conference Calendar MBI News Upcoming Events Industry Resources MBI News 04/29/13 Harvard Announces $50 Million Gift from the Blavatnik Family Foundation 04/29/13 FORMA Therapeutics and Celgene Corporation Establish Broad Strategic Collaboration to Advance Innovative Drugs Targeting Protein Homeostasis 04/23/13 Enanta Announces New Data From Phase 2b Interferon-Free Combination Studies with Protease Inhibitor ABT-450 for Hepatitis C Treatment to be Presented at EASL 04/09/13 Mersana Therapeutics Presents Positive Preclinical Data on Next-Generation Antibody-Drug Conjugate Technology at AACR Annual Meeting 04/02/13 Theraclone Sciences Announces Positive Top-line Data from Phase 1 Trial of Therapeutic Antibody for the Treatment of Human Cytomegalovirus Infection 04/01/13 Ra Pharmaceuticals Announces Broad Collaboration with Merck to Develop Cyclomimetics(TM) 03/28/13 T2 Biosystems Completes $40 Million Series E Financing to Support Clinical Programs and Commercialization of Sepsis Diagnostics 03/26/13 Avaxia Biologics Appoints Deborah S. Hartman, Ph.D. as Vice President, Research 03/25/13 Theraclone Sciences Secures $14 Million in Additional Financing 03/20/13 Enanta Pharmaceuticals Announces Pricing of Initial Public Offering 03/12/13 Allegro Diagnostics Announces BronchoGen™ Genomic Test for Improved Diagnosis of Lung Cancer Successfully Achieves Clinical Validation 03/09/13 STENTYS Self-Apposing® Stent Demonstrates Lowest Mortality Rate Among Large Heart Attack Trials 02/25/13 Avaxia Biologics Announces First Patient Dosed in Phase 1b Study of AVX-470 in Ulcerative Colitis 02/05/13 Verastem Initiates Phase 1/1b Clinical Trial of VS-6063 Plus Paclitaxel for Patients with Ovarian Cancer 01/29/13 OncoPep Initiates Phase 1/2a Clinical Trial with Multi-Peptide Vaccine to Treat Smoldering Multiple Myeloma 01/23/13 Mersana Therapeutics Expands Senior Leadership Team with Appointments of Peter Park, Ph.D., as VP of Biology and Wayne Foster, CPA, as VP of Finance 01/16/13 BaroFold and Lonza Announce a Technology Evaluation Agreement for PreEMT™, a High Pressure Protein Refolding Technology 01/09/13 GVK Biosciences and Onconova Therapeutics Establish Novel Joint Development Partnership to Advance New Drugs for Cancer 01/03/13 STENTYS Clinical Study Demonstrating Superiority of Self-Apposing® Stents Over Conventional Stents Published in American College of Cardiology Journal 12/20/12 Nuron Biotech Raises $80 Million from HealthCare Royalty Partners 12/18/12 Avaxia Biologics Raises $6.4 Million in Series B Financing 12/10/12 Nuron Biotech Acquires Commercial, Preventive Vaccine Meningitec™ from Pfizer 11/13/12 BaroFold and Boehringer Ingelheim Announce Strategic Agreement on PreEMT™ High Pressure Protein Refolding Technology 11/13/12 Nuron Biotech Completes Enrollment of a Pivotal Phase 3 Study for Proprietary Recombinant Human Interferon Beta-1b (NU100) in Relapsing Remitting Multiple Sclerosis 10/25/12 Thrasos Secures $35 Million to Fund THR-184 Phase 2 Clinical Program for Treatment of Acute Kidney Injury 10/25/12 Theraclone Sciences Initiates Phase 2 Viral Challenge Clinical Study of Therapeutic Antibody for the Treatment of Influenza A 10/24/12 CircuLite® Announces Two Presentations at Annual Meeting of the European Association for Cardio-Thoracic Surgery 10/23/12 Allegro Diagnostics Presents Positive AEGIS I Trial Results of BronchoGen™ Genomic Test to Improve Diagnosis of Lung Cancer at Annual CHEST Meeting 10/22/12 STENTYS Receives FDA Approval to Initiate First U.S. Clinical Trial With Self-Apposing® Stent 10/22/12 STENTYS Self-Apposing® Stent Continues to Demonstrate Low Mortality at One Year in APPOSITION III Trial 10/15/12 STENTYS to Present One-Year Interim Results From APPOSITION III Study at TCT Conference 10/15/12 CircuLite® Announces Four Presentations at Transcatheter Cardiovascular Therapeutics Conference 10/11/12 GNS Healthcare Expands Senior Management Team Adding Hans Winkler, Ph.D., as Chief Scientific Officer 10/10/12 Eric Rose, M.D., Named Chairman of the CircuLite^® Board of Directors 10/2/12 T2 Biosystems Named a "Fierce 15" Medical Device and Diagnostic Company of 2012 09/27/12 WWC Securities Launches New Boston-based Life Sciences Practice and Changes Name to Outcome Capital 09/19/12 GNS Healthcare Collaborates With a Leading CRO to Enable More Efficient and Cost-Effective Drug Development 09/19/12 Seaside Therapeutics Publishes Seminal Research Supporting the Disease-Modifying Potential of STX209 for the Treatment of Fragile X Syndrome 09/19/12 Baxter and Onconova Announce European Licensing Agreement for Anti-Cancer Compound Rigosertib 09/19/12 SpringLeaf Therapeutics Names Pieter Muntendam, MD, President and Chief Executive Officer 09/19/12 Aerpio Therapeutics Initiates Phase 1b/2a Trial of AKB-9778 in Diabetic Macular Edema 09/19/12 Seaside Therapeutics Named a "Fierce 15" Biotech Company for 2012 09/19/12 FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner 09/19/12 Mersana Therapeutics Named a "Fierce 15" Biotech Company for 2012 09/10/12 Theraclone Sciences Presents Phase 1 Results of TCN-032, its Therapeutic Antibody Directed at Influenza A, at ICAAC 2012 09/10/12 CircuLite® Receives CE Marking Approval for SYNERGY® Circulatory Support System 09/05/12 CircuLite® Presents Positive Hemodynamic, Exercise Tolerance and Quality of Life Data for SYNERGY® Circulatory Support System at Heart Failure Society of America Scientific Meeting 09/05/12 FORMA Therapeutics Appoints Dr. Rob Sarisky to Chief Business Officer 09/04/12 Jonathan DiVincenzo Joins Enzymatics as President and Chief Executive Officer 08/30/12 Aerpio Therapeutics Completes $27 Million Series A Financing 08/29/12 Theraclone Announces Pfizer Selects Next Target in Antibody Discovery Collaboration 08/27/12 Allegro Diagnostics to Present Clinical Trial Results of BronchoGen™ Genomic Test to Improve Diagnosis of Lung Cancer in Late-Breaking Abstract Session at CHEST 2012 08/22/12 Aerpio Therapeutics Hosts Scientific Symposium on Tie2 Pathway 08/14/12 GNS Healthcare and CHDI Foundation Collaborate to Build Computer Model of Huntington's Disease 08/07/12 Harvard Clinical Research Institute Successfully Completes Randomization in the DAPT Study 08/02/12 Founded by Enlight Biosciences, KNODE Partners with AstraZeneca and Other Partners 08/01/12 Adimab and Mersana Announce Antibody-Drug Conjugate Alliance 08/01/12 Acetylon Pharmaceuticals Initiates New Phase 1b Clinical Trial of Rocilinostat (ACY-1215) in Combination with Celgene's Revlimid(r) (Lenalidomide) and Dexamethasone for Patients with Multiple Myeloma 07/31/12 Mersana Therapeutics Raises $27M to Advance Fleximer® Antibody-drug Conjugates 07/11/12 Verastem Acquires Clinical-Stage FAK Inhibitor from Pfizer 06/19/12 Roche and Seaside Therapeutics Announce Landmark Alliance to Advance Novel Treatments for Fragile X Syndrome and Autism Spectrum Disorders 06/14/12 Rheonix Highlights First Fully Automated FFPE KRAS-Biomarker Assay at BIO International Convention 06/14/12 Theraclone Sciences Announces Initiation of a Phase 1 Clinical Trial of TCN-202, an Antibody in Development for the Treatment of Human Cytomegalovirus Infection 05/16/12 Ra Pharmaceuticals Unveils Hereditary Angioedema as Lead Program Leveraging its Cyclomimetic Discovery Platform 05/15/12 Theraclone Sciences Announces Positive Top-line Data from a Phase 1 Trial of its Therapeutic Antibody Directed at Influenza A 04/26/2012 Epizyme Forms Strategic Partnership with Industry Leader in Epigenetic Therapies, Celgene Corporation, to Develop Personalized Therapeutics for Genetically-Defined Cancers 04/09/2012 Nuron Biotech Expands Portfolio With Exclusive, Worldwide License for an Amyloid Beta 42 DNA Vaccine Candidate for Alzheimer’s Disease 03/20/2012 Aerpio Announces Positive Phase 1 Data on First-in-class Tie2 Activator, AKB-9778, in Development for Diabetic Macular Edema 03/07/2012 Mersana Therapeutics Enters Collaboration with Endo Pharmaceuticals to Develop Next-generation Antibody-drug Conjugates 03/05/2012 Nuron Biotech Expands Portfolio With License of Therapeutic and Prophylactic Hepatitis Vaccine Candidates 02/23/2012 Satori Pharmaceuticals Raises $15M in New Funding 02/21/2012 Enanta Enters Into Strategic Collaboration To Advance NS5A Inhibitor Candidate For HCV 02/13/2012 OncoPep Enters Exclusive License Agreement with Dana-Farber for Novel Multi-peptide Vaccine Technology for Hematologic Cancers 02/09/2012 Acetylon Announces $15 Million Strategic Equity Investment by Celgene Corporation 02/09/2012 Protalix Announces New Clinical Data on Taliglucerase Alfa to be Presented at the WORLD Lysosomal Disease Network Symposium 02/07/2012 Thrasos and Collaborators Publish Nature Medicine Research Article Detailing Potential Treatment Approach for Kidney Disease 02/02/2012 Lubiprostone Meets Primary Endpoint in Phase 3 Clinical Trial for Opioid-Induced Bowel Dysfunction (OBD) 01/13/2012 Nuron Biotech Licenses HibTITER® Vaccine to Mitsubishi Tanabe Pharma Corporation for Japanese Market 01/10/2012 FORMA Therapeutics Announces an Exclusive Cancer Drug Discovery Alliance Focused on Tumor Metabolism with Janssen Biotech Inc. 01/10/2012 Epizyme Achieves $4 Million Pre-Clinical Milestone Payment in Eisai Strategic Partnership 01/05/2012 FORMA Therapeutics Announces Collaboration with Boehringer Ingelheim to Develop Novel Oncology Drugs 01/04/2012 CircuLite Awarded Grant from Cardiovascular Medical Research and Education Fund to Develop Right-Heart Circulatory Support System for Patients with Pulmonary Arterial Hypertension (PAH) 12/15/2011 Rheonix, Inc. Announces Novel Microarray Production Technology to Support Multiplexed Endpoint Detection of Single Nucleotide Polymorphisms 11/30/2011 CircuLite® Raises $30 Million Series D Financing 11/22/2011 Asahi Kasei Pharma Corp. Acquires Artisan Pharma to Establish U.S. Presence; Wholly-owned Subsidiary Changes Name to Asahi Kasei Pharma America Corp 11/07/2011 SCYNEXIS Presents Data Demonstrating that SCY-635 Restores the Body’s Innate Immune Response to HCV and Could be an Effective Replacement for Recombinant Interferon 11/01/2011 Nuron Biotech Initiates Phase 3 Study of Proprietary Recombinant Human Interferon beta-1b in Relapsing Remitting Multiple Sclerosis 10/21/2011 Rib-X Pharmaceuticals’ RX-04 Program Yields Compounds with In Vitro Potency Against Multi-drug Resistant P. aeruginosa 10/21/2011 T2 Biosystems Announces the Presentation of Data on Direct Detection with T2Candida 10/20/2011 Proteostasis Therapeutics Announces Appointment of Mark J. Enyedy as Chief Executive Officer 10/19/2011 Arsanis Receives Grant from the Austrian Research Promotion Agency for Pre-Clinical and Clinical Development of Monoclonal Antibodies Against Severe Nosocomial Infections 10/14/2011 Epizyme Achieves $4 Million in Pre-Clinical Milestone Payments in GlaxoSmithKline Alliance to Discover and Develop Novel HMT Therapeutics 10/13/2011 Enanta Awarded up to $42.7 Million NIAID Contract to Develop a Novel Broad Spectrum Bicyclolide Antibiotic 09/21/2011 Theraclone Sciences Announces Initiation of Phase 1 Clinical Trial of TCN-032 for Influenza A 09/06/2011 Epizyme, Inc. Named a “Fierce 15” Biotech Company for 2011 09/06/2011 FORMA Therapeutics Named by FierceBiotech in the 2011 Fierce 15 09/06/2011 Rib-X Pharmaceuticals Named a 2011 Fierce 15 Company by FierceBiotech 09/06/2011 Theraclone Sciences Named a 2011 Fierce 15 Biotech by FierceBiotech 08/30/2011 Lantos Technologies Appoints Jeffrey C. Leathe as Chairman and CEO and Closes $4.1 Million Financing 08/17/2011 AIDS Researchers Isolate New Potent and Broadly Effective Antibodies Against HIV 07/27/2011 Rheonix Announces New SeptiCARD Data Demonstrating Rapid Septicemia Diagnosis 07/11/2011 Epizyme and Collaborators Publish Paper in Cancer Cell Supporting Use of DOT1L Histone Methyltransferase Inhibitors as Personalized Therapeutics for Genetically-Defined MLL-rearranged Leukemia Patients 07/11/2011 Patch may replace IV drug infusions – Boston Globe (SpringLeaf Therapeutics) 07/08/2011 SpringLeaf Therapeutics Announces Second Close of Series B Financing 07/06/2011 Rib-X Pharmaceuticals and Sanofi Sign a Research Collaboration Agreement on Novel Classes of Antibiotics 06/29/2011 Acetylon Pharmaceuticals Announces Completion of $27 Million Series B Round of Private Investor Financing 06/27/2011 FORMA Grants Genentech Exclusive Rights to Acquire a Pre-clinical Cancer Program 06/23/2011 The Leukemia & Lymphoma Society and Epizyme Partner to Develop Personalized Therapeutic for Genetically-Defined Mixed Lineage Leukemia (MLL) Patients 06/21/2011 Seaside Therapeutics Initiates Phase 2b Study of STX209 in Autism Spectrum Disorders 06/15/2011 Allegro Diagnostics Names Michael D. Webb President and Chief Executive Officer 06/02/2011 Seaside Therapeutics Initiates Pivotal Phase 3 Study of STX209 in Fragile X Syndrome 05/31/2011 Excelimmune Completes $10.5 Million Series B Financing 05/25/2011 Proteostasis Therapeutics & Elan Form Drug Discovery Initiative 05/18/2011 Seaside Therapeutics Publishes Review of Advances in the Treatment of FXS in ACS Chemical Neuroscience 05/12/2011 SpringLeaf Therapeutics Raises $15M Series B Financing 05/11/2011 The Leukemia & Lymphoma Society and Acetylon Pharmaceuticals Partner to Advance the Clinical Development of Acetylon's ACY-1215 Drug Candidate for Multiple Myeloma 04/25/2011 Acetylon Pharmaceuticals Adds HDAC Biology, Inflammation and Neurodegeneration Experts to its Scientific Advisory Board 04/18/2011 Idera Pharmaceuticals Publishes Data Demonstrating Novel Gene-silencing Oligonucleotide (GSO) Technology 04/04/2011 Abbott and Enanta Pressent Positive 12-week Results and 3-day Resistance Data from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C 04/04/2011 Harvard Clinical Research Institute and Saint Luke's Mid America Heart and Vascular Institute Complete Cost-effectiveness Analysis for SAPIEN Transcatheter Heart Valve 03/10/2011 Epizyme Enters Worldwide Strategic Partnership with Eisai for Cancer Therapeutics Targeting EZH2 Epigenetic Enzyme 03/03/2011 DUSA Pharmaceuticals Reports Full Year 2010 Corporate Highlights and Financial Results 02/28/2011 Arsanis Announces Series A Fundraising 01/19/2011 Epizyme Enters Worldwide Strategic Partnership with Eisai for Cancer Therapeutics Targeting EZH2 Epigenetic Enzyme 01/19/2011 Theraclone and Pfizer Enter into Infectious Disease and Cancer Antibody Discovery Collaboration 01/11/2011 Rib-X Pharmaceuticals Raises $20 Million to Advance its Industry-Leading Antibiotics Pipeline 01/10/2011 Epizyme Announces Strategic Alliance to Develop Epigenetic Therapeutics 01/07/2011 Emerald BioStructures Achieves Second Milestone and Expands Collaboration with UCB 12/15/2010 Adimab Announces New Discovery Programs with Eli Lilly, Genentech and Human Genome Sciences 12/08/2010 Anchor Therapeutics Publishes Discovery of Novel Pepducin as Potent Agonist of Stem Cell Receptor 11/18/2010 Decoding Autism - Forbes Magazine (Seaside Therapeutics) 11/17/2010 Eisai and FORMA Therapeutics Enter into Broad Drug Discovery Collaboration 11/16/2010 Proteostasis Therapeutics Enters into Research Collaboration with Harvard 09/28/2010 Pieris Signs Broad Collaboration with Sanofi-Aventis and Sanofi Pasteur to Develop Anticalin Therapeutics 09/10/2010 Good Start Genetics, Inc. Raises $18 Million to Develop and Launch Sequencing‐Based Pre‐Pregnancy Genetic Screening Tes 09/09/2010 Seaside Therapeutics Reports Positive Data from Phase 2 Study of STX209 in Autism Spectrum Disorders

	© 2013 MacDougall Biomedical Communications \| Privacy Policy